文献速递其他结缔组织病

雷诺现象患者进展为系统性硬化症:欧洲硬皮病试验与研究组多中心纵向注册研究VEDOSS的五年分析

Progression of patients with Raynaud's phenomenon to systemic sclerosis: a five-year analysis of the European Scleroderma Trial and Research group multicentre, longitudinal registry study for Very Early Diagnosis of Systemic Sclerosis (VEDOSS).
PubMed 文献 · Lancet Rheumatol · 2021-01-01

VEDOSS项目为多中心纵向注册研究,纳入1150例雷诺现象患者,其中764例符合VEDOSS标准,553例有至少一次随访。随访中位3.6年,133例达到2013年ACR-EULAR系统性硬化症分类标准,总体进展率52.4%。基线抗核抗体阴性者进展风险极低,仅37例中4例(10.8%)进展;系统性硬化症特异性自身抗体阳性合并肿胀手指者进展风险最高,17例中16例(94.1%)进展。

要点

  • 基线抗核抗体阴性是5年内不进展的强保护因素,37例中仅4例(10.8%)进展。
  • 系统性硬化症特异性自身抗体阳性合并肿胀手指者进展风险最高,17例中16例(94.1%)进展。
  • VEDOSS标准可用于雷诺现象患者的风险分层,支持临床管理和早期干预试验设计。

核心结论

  • VEDOSS项目结果为雷诺现象患者提供了分层风险评估工具,基线抗核抗体阴性识别出进展为系统性硬化症风险极低的患者,而存在一项或两项VEDOSS标准者随时间进展风险逐步升高。

研究设计与样本

  • VEDOSS项目为多中心纵向注册研究,在位于欧洲、北美和南美的20个国家的42个欧洲硬皮病试验与研究组中心进行。
  • 2010年3月1日至2018年10月4日共纳入1150例雷诺现象患者,其中764例(66.4%)符合VEDOSS标准纳入研究,553例(72.4%)有至少一次随访。
  • 553例随访患者中位随访3.6年(IQR 1.7-5.8),平均年龄45.9岁(SD 15.0),507例(91.7%)为女性,雷诺现象起病至入组中位时间4.0年(IQR 1.7-10.0)。

主要发现

  • 553例中254例(45.9%)完成研究(进展或随访满5年),其中133例达到主要终点,总体进展率52.4%。
  • 基线抗核抗体阴性者37例中仅4例(10.8%)在5年内进展,为与不进展关联最强的因素。
  • 基线系统性硬化症特异性自身抗体阳性合并肿胀手指者进展风险最高,17例中16例(94.1%)进展。
  • 基线时544例中401例(73.7%)抗核抗体可检出,527例中208例(39.5%)系统性硬化症特异性自身抗体阳性,505例中182例(36.0%)甲襞毛细血管镜异常,540例中96例(17.8%)有肿胀手指。
  • 共记录1885次随访访视。

关键数值与推荐

  • VEDOSS标准包括四项:抗核抗体阳性、肿胀手指、系统性硬化症特异性自身抗体阳性、甲襞毛细血管镜异常。
  • 主要终点为达到2013年ACR-EULAR系统性硬化症分类标准。
  • 基线抗核抗体阴性者5年进展率为10.8%(4/37)。
  • 基线系统性硬化症特异性自身抗体阳性合并肿胀手指者进展率为94.1%(16/17)。

临床怎么用

  • 作者认为VEDOSS分层工具可用于临床管理并帮助设计早期干预试验。
  • 作者指出基线抗核抗体阴性可识别进展为系统性硬化症风险极低的雷诺现象患者。
  • 作者指出雷诺现象患者存在一项或两项VEDOSS标准时,随时间进展为系统性硬化症的风险逐步升高。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Preliminary criteria for the very early diagnosis of systemic sclerosis (VEDOSS) have been previously proposed to identify signs and symptoms in patients with Raynaud's phenomenon. Patients with all signs or symptoms of the VEDOSS criteria already fulfil the 2013 American College of Rheumatology-European League Against Rheumatism (ACR-EULAR) classification criteria for systemic sclerosis. However, prospective data for the evolution to fulfilling these criteria do not exist. We therefore aimed to determine the clinical value of the VEDOSS criteria to identify patients with Raynaud's phenomenon who progress to systemic sclerosis within 5 years. METHODS: The VEDOSS project was a multicentre, longitudinal registry study done in 42 European Scleroderma Trial and Research group centres located in 20 countries in Europe, North America, and South America. Patients with Raynaud's phenomenon were eligible for enrolment. Those who had fulfilled the 1980 ACR or the 2013 ACR-EULAR classification criteria for systemic sclerosis, as well as of any other ACR or EULAR classification criteria for other definite connective tissue diseases at enrolment were excluded. Data were recorded each year during follow-up visits and included the four VEDOSS criteria (ie, positivity for antinuclear antibodies [ANAs], puffy fingers, systemic sclerosis-specific autoantibodies, and abnormal nailfold capillaroscopy). The primary endpoint was the fulfilment of the 2013 ACR-EULAR classification criteria for systemic sclerosis (ie, progression from enrolment to follow-up). Proportion of progressors and VEDOSS criteria interaction were reported descriptively. Predictors of progression of the distinct VEDOSS criteria interactions were determined based on the point prevalence at 5 years. To investigate the intermediate course of progression of the distinct VEDOSS criteria and their combinations, Kaplan-Meier analysis was done. RESULTS: Between March 1, 2010, and Oct 4, 2018, we enrolled 1150 patients with Raynaud's phenomenon in the VEDOSS database. 764 (66·4%) of 1150 patients met the VEDOSS criteria for study inclusion. Of the 764 patients, 553 (72·4%) had at least one available follow-up visit and the median duration of follow-up was 3·6 years (IQR 1·7-5·8). The mean age was 45·9 years (SD 15·0), 507 (91·7%) of 553 participants were female, and the median time since the onset of Raynaud's phenomenon was 4·0 years (IQR 1·7-10·0). At baseline, 401 (73·7%) of 544 patients with Raynaud's phenomenon had detectable ANA, with 208 (39·5%) of 527 patients positive for systemic sclerosis-specific autoantibodies. Nailfold capillaroscopy abnormalities were present in 182 (36·0%) of 505 patients and puffy fingers were detected in 96 (17·8%) of 540 at baseline. 1885 follow-up visits were recorded. 254 (45·9%) of 553 patients completed the study with progression or a 5-year follow-up; of whom, 133 reached the primary endpoint, resulting in an overall progression rate of 52·4%. The absence of ANA at baseline was the factor most strongly associated with a lack of progression within 5 years, with only four (10·8%) of 37 ANA-negative patients progressing. Conversely, positivity at baseline for systemic sclerosis-specific autoantibodies and puffy fingers was the combination having the highest risk of progression (16 [94·1%] of 17). INTERPRETATION: Our results from the VEDOSS project offers a useful tool for a stratified risk approach to patients with Raynaud's phenomenon. The absence of ANA is a strong protective factor that identifies patients with very low risk of developing systemic sclerosis whereas the presence of one or two VEDOSS criteria in patients with Raynaud's phenomenon confers a progressively higher risk for systemic sclerosis over time. This stratification tool can be used both for clinical management and to inform early interventional trials. FUNDING: European Scleroderma Trial And Research and World Scleroderma Foundation.

来源:Lancet Rheumatol,查看原文。版权归原作者所有。

引用

  1. Bellando-Randone S, Del Galdo F, Lepri G, et al. Progression of patients with Raynaud's phenomenon to systemic sclerosis: a five-year analysis of the European Scleroderma Trial and Research group multicentre, longitudinal registry study for Very Early Diagnosis of Systemic Sclerosis (VEDOSS). Lancet Rheumatol. 2021. PMID: 38287630. doi:10.1016/S2665-9913(21)00244-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。